ASX:OPTOpthea Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Opthea Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$2.87 -0.03 (-1.03 %) (As of 05/13/2020) Add Compare Share Today's RangeA$2.79Now: A$2.87▼A$2.9650-Day RangeA$2.15MA: A$2.58▼A$3.0252-Week RangeA$0.57Now: A$2.87▼A$4.15Volume504,572 shsAverage VolumeN/AMarket Capitalization$772.48 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Opthea. Previous Next 2.6 Community Rank Outperform VotesOpthea has received 18 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOpthea has received 17 “underperform” votes. (Add your “underperform” vote.)Community SentimentOpthea has received 51.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Opthea and other stocks. Vote “Outperform” if you believe OPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from A($0.05) to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opthea is -41.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opthea is -41.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpthea has a P/B Ratio of 10.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolASX:OPT Previous Symbol CUSIPN/A CIKN/A Webwww.opthea.com Phone61 3 9826 0399Debt Debt-to-Equity Ratio0.53 Current Ratio12.46 Quick Ratio12.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$152,584.00 Price / Sales5,062.68 Cash FlowA$0.28 per share Price / Cash Flow10.29 Book ValueA$0.27 per share Price / Book10.51Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares269,158,016Market Cap$772.48 million Next Earnings DateN/A OptionableNot Optionable Receive OPT News and Ratings via Email Sign-up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Opthea (ASX:OPT) Frequently Asked Questions How has Opthea's stock been impacted by COVID-19 (Coronavirus)? Opthea's stock was trading at A$2.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPT stock has increased by 9.5% and is now trading at A$2.87. View which stocks have been most impacted by Coronavirus. How were Opthea's earnings last quarter? Opthea Ltd (ASX:OPT) released its earnings results on Friday, August, 9th. The company reported ($0.09) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.00. View Opthea's earnings history. Has Opthea been receiving favorable news coverage? News coverage about OPT stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opthea earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutOpthea. Who are some of Opthea's key competitors? Some companies that are related to Opthea include Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), NanoViricides (NNVC), Vita Life Sciences (VLS), Pharmaxis (PXS) and Avivagen (VIV). View all competitors. Who are Opthea's key executives? Opthea's management team includes the following people: Dr. Megan Baldwin Ph.D., MAICD, MD, CEO & Exec. DirectorMr. Michael Tonroe, CFO & Company Sec.Mr. Richard Chadwick Ph.D., Head of Intellectual PropertyDr. Michael Gerometta, Head of CMC Devel.Dr. Ian Leitch, Director of Clinical Research What is Opthea's stock symbol? Opthea trades on the ASX under the ticker symbol "OPT." What is Opthea's stock price today? One share of OPT stock can currently be purchased for approximately A$2.87. How big of a company is Opthea? Opthea has a market capitalization of $772.48 million and generates $152,584.00 in revenue each year. What is Opthea's official website? The official website for Opthea is www.opthea.com. How can I contact Opthea? The company can be reached via phone at 61 3 9826 0399. This page was last updated on 6/1/2020 by MarketBeat.com Staff
